In recent years, multiple cardiovascular outcome trials (CVOT) have demonstrated that several antihyperglycemic agents can not only improve glycemic parameters, but also reduce the risk of cardiovascular events. These trials, originally designed to demonstrate CV safety, have provided valuable insights that can shift the focus of type 2 diabetes mellitus (T2DM) care beyond glucose control—into CV risk management and prevention. Consequently, a growing body of evidence is accumulating on the ability of certain drugs to reduce mortality and hospitalizations for worsening heart failure in high-risk patients with T2DM, leading to changes in CV indications and clinical practice guidelines & recommendations. This workshop will focus on one such recommendation—a joint publication by the American College of Cardiology (ACC) and American Diabetes Association (ADA) on CV risk reduction in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD). Through a didactic presentation, attendees will stay up-to-date on clinical advances, and learn how to translate the newest clinical trial research into their everyday practices.